Anja Rockstroh
Overview
Explore the profile of Anja Rockstroh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bidgood C, Philp L, Rockstroh A, Lehman M, Nelson C, Sadowski M, et al.
Cell Death Dis
. 2024 Jul;
15(7):513.
PMID: 39025852
Metabolic reprogramming and energetic rewiring are hallmarks of cancer that fuel disease progression and facilitate therapy evasion. The remodelling of oxidative phosphorylation and enhanced lipogenesis have previously been characterised as...
2.
Stylianou N, Sebina I, Matigian N, Monkman J, Doehler H, Rohl J, et al.
Clin Transl Immunology
. 2024 Feb;
13(2):e1488.
PMID: 38322491
Objectives: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus infection in pregnancy is associated with higher incidence of placental dysfunction, referred to by a few studies as a 'preeclampsia-like syndrome'....
3.
Janaththani P, Tevz G, Fernando A, Malik A, Rockstroh A, Kryza T, et al.
Res Sq
. 2023 Dec;
PMID: 38076926
Genome-wide association studies have linked Iroquois-Homeobox 4 (IRX4) as a robust expression quantitative-trait locus associated with prostate cancer (PCa) risk. However, the intricate mechanism and regulatory factors governing IRX4 expression...
4.
Adams M, Croft L, Urquhart A, Saleem M, Rockstroh A, Duijf P, et al.
Prostate
. 2023 Feb;
83(7):628-640.
PMID: 36811381
Background: Activation and regulation of androgen receptor (AR) signaling and the DNA damage response impact the prostate cancer (PCa) treatment modalities of androgen deprivation therapy (ADT) and radiotherapy. Here, we...
5.
Chawla S, Rockstroh A, Lehman M, Ratther E, Jain A, Anand A, et al.
Nat Commun
. 2022 Sep;
13(1):5680.
PMID: 36167836
Inter and intra-tumoral heterogeneity are major stumbling blocks in the treatment of cancer and are responsible for imparting differential drug responses in cancer patients. Recently, the availability of high-throughput screening...
6.
Tang Y, Rockstroh A, Sokolowski K, Lynam L, Lehman M, Thompson E, et al.
Breast Cancer Res
. 2022 Jan;
24(1):8.
PMID: 35078508
Background: Triple-negative breast cancers (TNBC) have a relatively poor prognosis and responses to targeted therapies. Between 25 and 39% of TNBCs are claudin-low, a poorly differentiated subtype enriched for mesenchymal,...
7.
Philp L, Rockstroh A, Sadowski M, Fard A, Lehman M, Tevz G, et al.
Endocr Relat Cancer
. 2021 Apr;
28(5):353-375.
PMID: 33794502
Hyperleptinaemia is a well-established therapeutic side effect of drugs inhibiting the androgen axis in prostate cancer (PCa), including main stay androgen deprivation therapy (ADT) and androgen targeted therapies (ATT). Given...
8.
Philp L, Rockstroh A, Lehman M, Sadowski M, Bartonicek N, Wade J, et al.
Endocr Relat Cancer
. 2020 Oct;
27(12):711-729.
PMID: 33112829
Adiponectin is an adipokine originally identified as dysregulated in obesity, with a key role in insulin sensitisation and in maintaining systemic energy balance. However, adiponectin is progressively emerging as having...
9.
Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer
Tousignant K, Rockstroh A, Poad B, Talebi A, Young R, Fard A, et al.
Cancer Metab
. 2020 Jun;
8:11.
PMID: 32577235
Background: Metabolic reprograming, non-mutational epigenetic changes, increased cell plasticity, and multidrug tolerance are early hallmarks of therapy resistance in cancer. In this temporary, therapy-tolerant state, cancer cells are highly sensitive...
10.
Kryza T, Bock N, Lovell S, Rockstroh A, Lehman M, Lesner A, et al.
Mol Oncol
. 2019 Oct;
14(1):105-128.
PMID: 31630475
Kallikrein-related peptidase 14 (KLK14) is one of the several secreted KLK serine proteases involved in prostate cancer (PCa) pathogenesis. While relatively understudied, recent reports have identified KLK14 as overexpressed during...